The collaboration allows Bio-Techne to sell USP monoclonal antibody/mAb and recombinant adeno-associated virus/AAV reference standards alongside its analytical solutions, like the Maurice system ...

Bio-Techne Corporation (NASDAQ:TECH) is one of the best S&P 500 stocks with huge upside potential. On June 24, Bio-Techne Corporation announced a distribution agreement with the US Pharmacopeia/USP.

The collaboration allows Bio-Techne to sell USP monoclonal antibody/mAb and recombinant adeno-associated virus/AAV reference standards alongside its analytical solutions, like the Maurice system, to ...

Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities.

Bio-Techne Corporation (NASDAQ: TECH) today announced a distribution agreement with the U.S. Pharmacopeia (USP) that enables the Company to sell USP monoclonal antibody (mAb) and recombinant adeno ...

MINNEAPOLIS, June 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced a distribution agreement with the U.S. Pharmacopeia (USP) that enables the Company to sell USP ...

Bio-Techne and USP Announce Collaboration to Accelerate Monoclonal Antibody and Gene Therapy Product Development By Bio-Techne Corporation, U.S. Pharmacopeia Jun 24, 2025 Updated Jun 24, 2025 ...

Is the Defense Department still preparing to fight biological warfare as if it’s 1970? When preparing for biological warfare, most nations picture scenarios in which an enemy openly sprays traditional ...

The production of the movie about the unit, which is thought to have undertaken covert biological and chemical warfare research in China during World War II, was announced in August 2020.

Police in Germany have raided the home of a teenage boy suspected of making and storing ricin, a highly toxic and deadly biological warfare agent.

The film discusses the dangers of biological warfare (BW) and its potential impact on civilian populations, emphasizing the importance of public health systems in combating such threats. It ...

Climb Bio has expanded its pipeline with the exclusive license agreement for CLYM116, a novel anti-APRIL monoclonal antibody, targeting significant unmet medical needs in immune-mediated diseases.